TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This phase IB/II trial studies the best dose of TP-0903 and how well it works when given
alone or with azacitidine in treating patients with FLT3 gene mutated acute myeloid leukemia.
TP-0903 may stop the growth of cancer cells by blocking some of the enzymes needed for cell
growth. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of
cancer cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. Giving TP-0903 alone or with azacitidine may kill more cancer cells.